Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R)-Viloxazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.97 |
| ▸ | HTR2A | P28223 | 4/20 | 0.97 |
| ▸ | HTR2B | P41595 | 2/20 | 0.97 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.78 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.60 |
| ▸ | HTR3A | P46098 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | MLNR | O43193 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Viloxazine SCHEMBL300741 | 1.00 | SLC6A4 (0.97) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| (S)-Viloxazine SCHEMBL25394508 | 1.00 | SLC6A4 (0.97) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| Viloxazine SCHEMBL29362568 | 1.00 | SLC6A4 (0.97) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| (R)-Viloxazine SCHEMBL30589854 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| Viloxazine SCHEMBL29359040 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| Viloxazine SCHEMBL34168 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| (S)-Viloxazine SCHEMBL2524730 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| (S)-Viloxazine SCHEMBL31126415 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| (R)-Viloxazine SCHEMBL2524727 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| Viloxazine SCHEMBL1651391 | 0.96 | SLC6A4 (0.95) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707645-A | Synthesis method of viloxazine hydrochloride product impurities | 西安远大科创医药科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119707868-A | Willoxazine hydrochloride product impurity and synthetic method and application thereof | 西安远大科创医药科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119707851-A | Willoxazine hydrochloride product impurity and synthetic method and application thereof | 西安远大科创医药科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4493550-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | Supernus Pharmaceuticals, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-119064489-A | Method for detecting enantiomer in viloxazine medicine | 苏州恩华生物医药科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118451064-A | Process for preparing derivatives of substituted morpholines | 苏佩努斯制药公司 | 2024-08-06 | — | — | CN | disclosed |
| US-11964951-B2 | Process of making derivatives of substituted morpholines | SUPERNUS PHARMACEUTICALS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230295100-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | SUPERNUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023177845-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | SUPERNUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295100-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | UGT2B7, CYP3A7, CYP3A4 | SLC6A2 104/4885SLC6A4 87/4885SLC6A3 117/4885 |
| US-11964951-B2 | Process of making derivatives of substituted morpholines | UGT2B7, CYP3A7, CYP3A4 | SLC6A2 104/4885SLC6A4 87/4885SLC6A3 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.